Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
24-2002
📡 5G SEP • ETSI DeclaredOverview
Parties
Defendant
SAMSUNG BIOEPIS CO., LTD. Operating Company
Represented By
0 Attorneys ListedPlaintiff - Appellee
REGENERON PHARMACEUTICALS, INC. Operating Company
Represented By
12 Attorneys ListedPaul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas, New York, NY 10019-6064
Paul, Weiss, Rifkind, Wharton & Garrison LLP
2001 K Street, NW, Washington, DC 20006
Defendant - Appellant
BIOCON BIOLOGICS INC. Operating Company
Represented By
7 Attorneys ListedNeil McLaughlin, Litigation Counsel
Rakoczy Molino Mazzochi Siwik LLP
6 W Hubbard Street, Chicago, IL 60654
MYLAN PHARMACEUTICALS INC. Operating Company
Represented By
7 Attorneys ListedNeil McLaughlin, Litigation Counsel
Rakoczy Molino Mazzochi Siwik LLP
6 W Hubbard Street, Chicago, IL 60654
Court & Judges
Court
Court of Appeals for the Federal Circuit (cafc)
Global Patent Family Cross-Litigation Radar
CasLoc 360° RadarMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
No Co-Pending Disputes Detected in Current Index
There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP • ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.
Patents Involved
No asserted patent numbers detected in initial docket filings yet.